Literature DB >> 23725361

Prescription opioid abuse: challenges and opportunities for payers.

Nathaniel P Katz1, Howard Birnbaum, Michael J Brennan, John D Freedman, Gary P Gilmore, Dennis Jay, George A Kenna, Bertha K Madras, Lisa McElhaney, Roger D Weiss, Alan G White.   

Abstract

OBJECTIVES: Prescription opioid abuse and addiction are serious problems with growing societal and medical costs, resulting in billions of dollars of excess costs to private and governmental health insurers annually. Although difficult to accurately assess, prescription opioid abuse also leads to increased insurance costs in the form of property and liability claims, and costs to state and local governments for judicial, emergency, and social services. This manuscript's objective is to provide payers with strategies to control these costs, while supporting safe use of prescription opioid medications for patients with chronic pain.
METHOD: A Tufts Health Care Institute Program on Opioid Risk Management meeting was convened in June 2010 with private and public payer representatives, public health and law enforcement officials, pain specialists, and other stakeholders to present research and develop recommendations on solutions that payers might implement to combat this problem.
RESULTS: While protecting access to prescription opioids for patients with pain, private and public payers can implement strategies to mitigate financial risks associated with opioid abuse, using internal strategies such as formulary controls, claims data surveillance, and claims matching; and external policies and procedures that support and educate physicians on reducing opioid risks among patients with chronic pain.
CONCLUSIONS: Reimbursement policies, incentives, and health technology systems that encourage physicians to use universal precautions, to consult prescription monitoring program (PMP) data, and to implement Screening, Brief Intervention, and Referral to Treatment protocols have a high potential to reduce insurer risks while addressing a serious public health problem.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23725361      PMCID: PMC3680126     

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  59 in total

1.  Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy.

Authors:  Nathaniel P Katz; Summer Sherburne; Michael Beach; Robert J Rose; Janet Vielguth; Joyce Bradley; Gilbert J Fanciullo
Journal:  Anesth Analg       Date:  2003-10       Impact factor: 5.108

2.  Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations.

Authors:  M Weintraub; S Singh; L Byrne; K Maharaj; L Guttmacher
Journal:  JAMA       Date:  1991-11-06       Impact factor: 56.272

3.  Effect of the requirement for triplicate prescriptions for benzodiazepines in New York State.

Authors:  M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1991-08       Impact factor: 6.875

4.  Opioids, chronic pain, and addiction in primary care.

Authors:  Declan T Barry; Kevin S Irwin; Emlyn S Jones; William C Becker; Jeanette M Tetrault; Lynn E Sullivan; Helena Hansen; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  J Pain       Date:  2010-06-02       Impact factor: 5.820

5.  A chart review of the ordering and documentation of urine toxicology screens in a cancer center: do they influence patient management?

Authors:  S D Passik; J Schreiber; K L Kirsh; R K Portenoy
Journal:  J Pain Symptom Manage       Date:  2000-01       Impact factor: 3.612

6.  New York State's Triplicate Prescription Program.

Authors:  J L Eadie
Journal:  NIDA Res Monogr       Date:  1993

7.  A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population.

Authors:  Dennis Ross-Degnan; Linda Simoni-Wastila; Jeffrey S Brown; Xiaoming Gao; Connie Mah; Leon E Cosler; Thomas Fanning; Peter Gallagher; Carl Salzman; Richard I Shader; Thomas S Inui; Stephen B Soumerai
Journal:  Int J Psychiatry Med       Date:  2004       Impact factor: 1.210

8.  Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database.

Authors:  Vincent Pradel; Xavier Thirion; Eléonore Ronfle; Alain Masut; Joëlle Micallef; Bernard Bégaud
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-07       Impact factor: 2.890

9.  Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000.

Authors:  Margaret A Caudill-Slosberg; Lisa M Schwartz; Steven Woloshin
Journal:  Pain       Date:  2004-06       Impact factor: 6.961

10.  A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in medicaid patients with chronic psychiatric and neurologic disorders.

Authors:  Linda Simoni-Wastila; Dennis Ross-Degnan; Connie Mah; Xiaoming Gao; Jeffrey Brown; Leon E Cosler; Thomas Fanning; Peter Gallagher; Carl Salzman; Stephen B Soumerai
Journal:  Clin Ther       Date:  2004-02       Impact factor: 3.393

View more
  19 in total

1.  New Perspectives in the Treatment of Opioid-Induced Respiratory Depression.

Authors:  Loretta Fala; John A Welz
Journal:  Am Health Drug Benefits       Date:  2015-10

Review 2.  What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.

Authors:  Tamara M Haegerich; Leonard J Paulozzi; Brian J Manns; Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2014-10-14       Impact factor: 4.492

Review 3.  Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety.

Authors:  Kyle Simon; Stacey L Worthy; Michael C Barnes; Benjamin Tarbell
Journal:  Ther Adv Drug Saf       Date:  2015-04

4.  Medicaid prior authorization and opioid medication abuse and overdose.

Authors:  Gerald Cochran; Adam J Gordon; Walid F Gellad; Chung-Chou H Chang; Wei-Hsuan Lo-Ciganic; Carroline Lobo; Evan Cole; Winfred Frazier; Ping Zheng; David Kelley; Julie M Donohue
Journal:  Am J Manag Care       Date:  2017-05-01       Impact factor: 2.229

5.  The development and feasibility of a pharmacy-delivered opioid intervention in the emergency department.

Authors:  Erin L Winstanley; Rebecca Mashni; Sydney Schnee; Nate Miller; Susan M Mashni
Journal:  J Am Pharm Assoc (2003)       Date:  2017 Mar - Apr

Review 6.  Inappropriate opioid prescription after surgery.

Authors:  Mark D Neuman; Brian T Bateman; Hannah Wunsch
Journal:  Lancet       Date:  2019-04-13       Impact factor: 79.321

7.  A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence.

Authors:  Azmi F Nasser; Christian Heidbreder; Roberto Gomeni; Paul J Fudala; Bo Zheng; Mark K Greenwald
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

8.  The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid Program.

Authors:  Hyunjee Kim; Daniel M Hartung; Reside L Jacob; Dennis McCarty; K John McConnell
Journal:  Psychiatr Serv       Date:  2016-01-14       Impact factor: 3.084

9.  Prescription Opioid Quality Measures Applied Among Pennsylvania Medicaid Enrollees.

Authors:  Gerald Cochran; Wei-Hsuan Lo-Ciganic; Walid F Gellad; Adam J Gordon; Evan Cole; Carroline Lobo; Winfred Frazier; Ping Zheng; Chung-Chou H Chang; David Kelley; Julie M Donohue
Journal:  J Manag Care Spec Pharm       Date:  2018-09

10.  Opioids in Georgia Medicaid: Gender and Insurance Disparities in Utilization and Potential Inappropriate Prescribing Practices.

Authors:  Jayani Jayawardhana; Amanda J Abraham; Henry N Young; Matthew Perri
Journal:  J Pharm Health Serv Res       Date:  2018-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.